Neuralstem shares move on spinal cord injury trial go-ahead
This article was originally published in Scrip
Executive Summary
Shares in US stem cell company Neuralstem rose by 5% to close at $1.29 on 14 January after it gained US FDA permission to start a Phase I trial of its lead cell therapy candidate NSI-566 in chronic spinal cord injury patients.